CROI 2015 Program and Abstracts

Abstract Listing

Poster Abstracts

Conclusions: In adults receiving an rPI, rosuvastatin 10 mg/day for 12 weeks yielded larger decreases in total and LDL cholesterol than rPI switching, and was better tolerated. 734 Application of New ACC/AHA Cholesterol Guidelines to an HIV Clinical Care Cohort Mosepele Mosepele 4 ; Susan Regan 1 ; James B. Meigs 1 ; Steven Grinspoon 1 ;Virginia A.Triant 1 1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 4 Harvard School of Public Health, Boston, MA, US Background: New cholesterol guidelines were issued by the American College of Cardiology (ACC)/ American Heart Association (AHA) in 2013. The impact of the new guidelines on HIV-infected patients is unknown. Our objective was to compare recommendations for statin use under the new guidelines with the established Adult Treatment Panel III (ATPIII) cholesterol guidelines in a large cohort of HIV-infected patients. Methods: Using the Partners HealthCare System HIV longitudinal cohort, we determined patients’ eligibility for statin therapy under the ACC/AHA and ATPIII guidelines as of 2008. We followed them through 2013 to observe actual statin prescription rates, indication for statin recommendations, and cardiovascular disease (CVD) event rates (CHD for ATPIII and atherosclerotic CVD for ACC/AHA) by statin recommendation status (ACC/AHA only, ATPIII only, both, or neither). Results: In a clinical care cohort of 2239 HIV-infected patients over age 18, 936 (41.8%) patients were recommended for statin therapy by the ACC/AHA guidelines compared with 575 (25.7%) by the ATPIII guidelines. Actual statin prescription rates for patients meeting guidelines for statin therapy were 47% for ACC/AHA and 65% for ATPIII. Of the 405 (18%) patients with discordant statin recommendations, 95%were recommended to be on statin therapy by ACC/AHA and not ATPIII. The most common indication for statin use under the ACC/AHA guidelines was CVD risk ≥ 7.5% by the new ACC/AHA risk prediction algorithm, and this was the only indication for 46% of patients recommended for statin therapy. Among the group of patients with a CVD outcome event, statin therapy was recommended for 44% of patients by ATPIII and 62% by ACC/AHA. When only one guideline recommended statin therapy for the group of patients with CVD events, the vast majority of cases (39/40) would have qualified for statin therapy by ACC/AHA but not by ATPIII. Conclusions: In an HIV clinical care cohort, the new ACC/AHA cholesterol guidelines recommend that a higher proportion of patients be on statin therapy and identify an increased proportion of patients with CVD outcome events compared with ATPIII. Despite this increase, nearly 40 percent of patients with a CVD event would not have qualified for statin therapy by the ACC/AHA guidelines. This gap may reflect the novel mechanism of HIV-associated CVD which is not accounted for in general-population guidelines and underscores the need for HIV-specific primary CVD prevention trials.

Poster Abstracts

WEDNESDAY, FEBRUARY 25, 2015 Session P-P3 Poster Session 2:30 pm– 4:00 pm ART: Cardiovascular Risk and Hypertension 735 ICAM-1 Overexpression Induced by Abacavir is Mediated by P2X 7 Receptors Carmen de Pablo;Victor Collado-Diaz; Samuel Orden; Cesar Rios-Navarro; Juan Esplugues; Angeles Alvarez University of Valencia, Valencia, Spain Poster Hall

Background: The use of abacavir has been associated with cardiovascular disease. In earlier studies, we have demonstrated that abacavir induces an increase in endothelial ICAM-1 expression and promotes leukocyte recruitment through Mac-1/ICAM-1 interaction. Given the chemical structure of abacavir, we have previously explored the link between abacavir and its proinflammatory effects by interfering in the purine signalling pathway, and have seen that ATP and its P2X 7 receptors are involved in the leukocyte accumulation induced by abacavir. The aim of the present study was to evaluate the role of ATP and its receptors in the endothelial ICAM-1 overexpression induced by abacavir. Methods: Human umbilical vein or arterial endothelial cells (HUVEC or HUAEC, respectively) were pre-treated with antagonists of P2X 7 ATP receptors [oxATP (600 m mol/L, 30 min) or A804598 (1 m mol/L, 30 min)] prior to administration of abacavir (10 m mol/L, 24h). Subsequently, ICAM-1 expression was measured by flow cytometry. Data represent the

452

CROI 2015